The role of vaccines in combatting antimicrobial resistance.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
accepted:
09
12
2020
pubmed:
6
2
2021
medline:
24
7
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
The use of antibiotics has enabled the successful treatment of bacterial infections, saving the lives and improving the health of many patients worldwide. However, the emergence and spread of antimicrobial resistance (AMR) has been highlighted as a global threat by different health organizations, and pathogens resistant to antimicrobials cause substantial morbidity and death. As resistance to multiple drugs increases, novel and effective therapies as well as prevention strategies are needed. In this Review, we discuss evidence that vaccines can have a major role in fighting AMR. Vaccines are used prophylactically, decreasing the number of infectious disease cases, and thus antibiotic use and the emergence and spread of AMR. We also describe the current state of development of vaccines against resistant bacterial pathogens that cause a substantial disease burden both in high-income countries and in low- and medium-income countries, discuss possible obstacles that hinder progress in vaccine development and speculate on the impact of next-generation vaccines against bacterial infectious diseases on AMR.
Identifiants
pubmed: 33542518
doi: 10.1038/s41579-020-00506-3
pii: 10.1038/s41579-020-00506-3
pmc: PMC7861009
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
287-302Références
Kapoor, G., Saigal, S. & Elongavan, A. Action and resistance mechanisms of antibiotics: a guide for clinicians. J. Anaesthesiol. Clin. Pharmacol. 33, 300–305 (2017).
pubmed: 29109626
pmcid: 5672523
Mladenovic-Antic, S. et al. Correlation between antimicrobial consumption and antimicrobial resistance of Pseudomonas aeruginosa in a hospital setting: a 10-year study. J. Clin. Pharm. Ther. 41, 532–537 (2016).
pubmed: 27511808
Hay, S. I. et al. Measuring and mapping the global burden of antimicrobial resistance. BMC Med. 16, 78 (2018).
pubmed: 29860943
pmcid: 5985573
IACG No Time To Wait: Securing The Future From Drug-Resistant Infections (2019).
United Nations. Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance, A/71/L.2. 22 (2016).
Aslam, B. et al. Antibiotic resistance: a rundown of a global crisis. Infect. Drug Resist. 11, 1645–1658 (2018).
pubmed: 30349322
pmcid: 6188119
Rappuoli, R., Santoni, A. & Mantovani, A. Vaccines: an achievement of civilization, a human right, our health insurance for the future. J. Exp. Med. 216, 7–9 (2019).
pubmed: 30510147
pmcid: 6314523
Kennedy, D. A. & Read, A. F. Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance. Proc. Natl Acad. Sci. USA 115, 12878–12886 (2018). This review compares emergence of drug resistance and vaccine resistance and explains why vaccine resistance is not a major concern.
pubmed: 30559199
pmcid: 6304978
Baker, S. J., Payne, D. J., Rappuoli, R. & De Gregorio, E. Technologies to address antimicrobial resistance. Proc. Natl Acad. Sci. USA 115, 12887–12895 (2018). This review describes how innovative vaccine technologies have the potential to boost the development of vaccines targeting several classes of multidrug-resistant bacteria.
pubmed: 30559181
pmcid: 6304975
Klugman, K. P. & Black, S. Impact of existing vaccines in reducing antibiotic resistance: Primary and secondary effects. Proc. Natl Acad. Sci. USA 115, 12896–12901 (2018).
pubmed: 30559195
pmcid: 6304973
Jansen, K. U., Knirsch, C. & Anderson, A. S. The role of vaccines in preventing bacterial antimicrobial resistance. Nat. Med. 24, 10–19 (2018). This review highlights the value of vaccines as one of the modalities to combat AMR globally, using select examples.
pubmed: 29315295
Cassini, A. et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 19, 56–66 (2019).
pubmed: 30409683
pmcid: 6300481
CDC. Antibiotic Resistance Threats in the United States, 2019. https://www.cdc.gov/DrugResistance/Biggest-Threats.html (Department of Health and Human Services, 2019). This is a CDC report with the latest national death and infection estimates that underscore the continued threat of antibiotic resistance in the USA.
World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1 (2017). This WHO document reports a list of antibiotic-resistant bacteria to help in prioritizing research and development investments for new and effective interventions
CDC, Healthcare-associated infections, https://www.cdc.gov/hai/patientsafety/ar-hospitals.html
Hersh, A. L., Chambers, H. F., Maselli, J. H. & Gonzales, R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch. Intern. Med. 168, 1585–1591 (2008).
pubmed: 18663172
Prosperi, M. et al. Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in the genomic era: a cross-sectional study. Sci. Rep. 3, 1902 (2013).
pubmed: 23712667
pmcid: 3664956
Khan, M. S. et al. ‘LMICs as reservoirs of AMR’: a comparative analysis of policy discourse on antimicrobial resistance with reference to Pakistan. Health Policy Plan. 34, 178–187 (2019).
pubmed: 30977804
FAO Global Forum on Food Security and Nutrition, http://www.fao.org/3/cb0863en/cb0863en.pdf
Founou, R. C., Founou, L. L. & Essack, S. Y. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS ONE 12, e0189621 (2017). This study analyses the published literature on the clinical and economic implications of AMR in developing countries.
pubmed: 29267306
pmcid: 5739407
Ayukekbong, J. A., Ntemgwa, M. & Atabe, A. N. The threat of antimicrobial resistance in developing countries: causes and control strategies. Antimicrob. Resist. Infect. Control. 6, 47 (2017).
pubmed: 28515903
pmcid: 5433038
Bagnoli, F. & Payne, D. J. Reaction: alternative modalities to address antibiotic-resistant pathogens. Chem 3, 369–372 (2017).
Romanò, L. et al. Hepatitis B vaccination. Hum. Vaccin. Immunother. 11, 53–57 (2015).
pubmed: 25483515
Zanetti, A. R., Van Damme, P. & Shouval, D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26, 6266–6273 (2008).
pubmed: 18848855
Octavia, S. et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J. Infect. Dis. 205, 1220–1224 (2012).
pubmed: 22416243
Cherry, J. D. Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N. Engl. J. Med. 367, 785–787 (2012).
pubmed: 22894554
Mooi, F. R. et al. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66, 670–675 (1998).
pubmed: 9453625
pmcid: 107955
Mishra, R. P., Oviedo-Orta, E., Prachi, P., Rappuoli, R. & Bagnoli, F. Vaccines and antibiotic resistance. Curr. Opin. Microbiol. 15, 596–602 (2012).
pubmed: 22981392
Miller, E., Andrews, N. J., Waight, P. A., Slack, M. P. & George, R. C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect. Dis. 11, 760–768 (2011).
pubmed: 21621466
Moore, M. R. et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197, 1016–1027 (2008).
pubmed: 18419539
Lipsitch, M. & Siber, G. R. How can vaccines contribute to solving the antimicrobial resistance problem? mBio 7, e00428-16 (2016). This minireview describes the significant contributions of current vaccines and the potential of future vaccines in controlling AMR and elucidates the mechanisms by which this can occur.
pubmed: 27273824
pmcid: 4959668
Sihvonen, R., Siira, L., Toropainen, M., Kuusela, P. & Patari-Sampo, A. Streptococcus pneumoniae antimicrobial resistance decreased in the Helsinki Metropolitan Area after routine 10-valent pneumococcal conjugate vaccination of infants in Finland. Eur. J. Clin. Microbiol. Infect. Dis. 36, 2109–2116 (2017).
pubmed: 28612153
John, T. J., Cherian, T. & Raghupathy, P. Haemophilus influenzae disease in children in India: a hospital perspective. Pediatr. Infect. Dis. J. 17, S169–S171 (1998).
pubmed: 9781753
Oliver, S. P., Murinda, S. E. & Jayarao, B. M. Impact of antibiotic use in adult dairy cows on antimicrobial resistance of veterinary and human pathogens: a comprehensive review. Foodborne Pathog. Dis. 8, 337–355 (2011).
pubmed: 21133795
No authors. Standing up to antimicrobial resistance. Nat Rev Microbiol 8, 836 (2010).
McEwen, S. A. & Fedorka-Cray, P. J. Antimicrobial use and resistance in animals. Clin. Infect. Dis. 34 (Suppl. 3), S93–S106 (2002).
pubmed: 11988879
Hoelzer, K. et al. Vaccines as alternatives to antibiotics for food producing animals. Part 1: challenges and needs. Vet. Res. 49, 64 (2018).
pubmed: 30060757
pmcid: 6066911
Tekle, Y. I. et al. Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. PLoS ONE 7, e50688 (2012).
pubmed: 23227198
pmcid: 3515573
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01887912 (2013).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03090191?term=vaccine&cond=clostridium+difficile&rank=7 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02316470?term=vaccine (2014).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04026009 (2019).
Pechine, S., Bruxelle, J. F., Janoir, C. & Collignon, A. Targeting clostridium difficile surface components to develop immunotherapeutic strategies against Clostridium difficile infection. Front. Microbiol. 9, 1009 (2018).
pubmed: 29875742
pmcid: 5974105
Starks, C. M. et al. Optimization and qualification of an assay that demonstrates that a FimH vaccine induces functional antibody responses in women with histories of urinary tract infections. Hum. Vaccin. Immunother. https://doi.org/10.1080/21645515.2020.1770034 (2020).
doi: 10.1080/21645515.2020.1770034
pubmed: 33325785
pmcid: 8078672
Huttner, A. & Gambillara, V. The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli. Clin. Microbiol. Infect. 24, 1046–1050 (2018).
pubmed: 29803843
Huttner, A. et al. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial. Lancet Infect. Dis. 17, 528–537 (2017).
pubmed: 28238601
Fattom, A. et al. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: phase III randomized study. Hum. Vaccin. Immunother. 11, 632–641 (2015).
pubmed: 25483694
pmcid: 4514248
Fowler, V. G. et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309, 1368–1378 (2013).
pubmed: 23549582
Pozzi, C. et al. Vaccines for Staphylococcus aureus and target populations. Curr. Top. Microbiol. Immunol. 409, 491–528 (2017).
pubmed: 28197738
Edwards, J. L., Jennings, M. P. & Seib, K. L. Neisseria gonorrhoeae vaccine development: hope on the horizon? Curr. Opin. Infect. Dis. 31, 246–250 (2018).
pubmed: 29601324
Vincent, L. R. & Jerse, A. E. Biological feasibility and importance of a gonorrhea vaccine for global public health. Vaccine 37, 7419–7426 (2018).
pubmed: 29680200
Petousis-Harris, H. et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390, 1603–1610 (2017).
pubmed: 28705462
Craig, A. P. et al. The potential impact of vaccination on the prevalence of gonorrhea. Vaccine 33, 4520–4525 (2015).
pubmed: 26192351
pmcid: 4743649
Petousis-Harris, H. & Radcliff, F. J. Exploitation of Neisseria meningitidis group B OMV vaccines against N. gonorrhoeae to inform the development and deployment of effective gonorrhea vaccines. Front. Immunol. 10, 683 (2019).
pubmed: 31024540
pmcid: 6465565
University of Alabama at Birmingham NIH study to explore vaccine for gonorrhea prevention. https://www.uab.edu/news/health/item/10852-nih-study-to-explore-vaccine-for-gonorrhea-prevention (2019).
Raterman, E. L. & Jerse, A. E. Female mouse model of Neisseria gonorrhoeae infection. Methods Mol. Biol. 1997, 413–429 (2019).
pubmed: 31119637
Edwards, J. L. & Apicella, M. A. The molecular mechanisms used by Neisseria gonorrhoeae to initiate infection differ between men and women. Clin. Microbiol. Rev. 17, 965–981 (2004).
pubmed: 15489357
pmcid: 523569
The Boston Consulting Group. Vaccines to tackle drug resistant infections. An evaluation of R&D opportunities (2018). This report evaluates the development potential of vaccines against pathogens with high levels of AMR.
Priebe, G. P. & Goldberg, J. B. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev. Vaccines 13, 507–519 (2014).
pubmed: 24575895
pmcid: 4521563
Doring, G., Meisner, C. & Stern, M. A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 104, 11020–11025 (2007).
pubmed: 17585011
pmcid: 1904125
Pier, G. B. et al. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine. Infect. Immun. 62, 3972–3979 (1994).
pubmed: 8063415
pmcid: 303055
Rello, J. et al. A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Crit. Care 21, 22 (2017).
pubmed: 28159015
pmcid: 5291979
Bianconi, I. et al. Genome-based approach delivers vaccine candidates against Pseudomonas aeruginosa. Front. Immunol. 9, 3021 (2018).
pubmed: 30687303
Choi, M., Tennant, S. M., Simon, R. & Cross, A. S. Progress towards the development of Klebsiella vaccines. Expert Rev. Vaccines 18, 681–691 (2019).
pubmed: 31250679
pmcid: 6656602
Seeberger, P. H. et al. A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant Klebsiella pneumoniae. Angew. Chem. Int. Ed. 56, 13973–13978 (2017).
Zigterman, J. W. et al. Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect. Immun. 47, 421–428 (1985).
pubmed: 3881349
pmcid: 263186
Feldman, M. F. et al. A promising bioconjugate vaccine against hypervirulent Klebsiella pneumoniae. Proc. Natl Acad. Sci. USA 116, 18655–18663 (2019).
pubmed: 31455739
pmcid: 6744904
Follador, R. et al. The diversity of Klebsiella pneumoniae surface polysaccharides. Microb. Genom. 2, e000073 (2016).
pubmed: 28348868
pmcid: 5320592
Hegerle, N. et al. Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE 13, e0203143 (2018).
pubmed: 30188914
pmcid: 6126813
Lee, W. H. et al. Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. Exp. Mol. Med. 47, e183 (2015).
pubmed: 26358222
pmcid: 4650931
Martin, R. M. et al. Molecular epidemiology of colonizing and infecting isolates of Klebsiella pneumoniae. mSphere https://doi.org/10.1128/mSphere.00261-16 (2016).
doi: 10.1128/mSphere.00261-16
pubmed: 27777984
pmcid: 5071533
World Health Organization. Typhoid vaccines: WHO position paper, March 2018 - recommendations. Vaccine 37, 214–216 (2019).
pubmed: 29661581
MacLennan, C. A., Martin, L. B. & Micoli, F. Vaccines against invasive Salmonella disease: current status and future directions. Hum. Vaccin. Immunother. 10, 1478–1493 (2014).
pubmed: 24804797
pmcid: 4185946
Lin, F. Y. et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N. Engl. J. Med. 344, 1263–1269 (2001).
pubmed: 11320385
Wahid, R., Salerno-Goncalves, R., Tacket, C. O., Levine, M. M. & Sztein, M. B. Cell-mediated immune responses in humans after immunization with one or two doses of oral live attenuated typhoid vaccine CVD 909. Vaccine 25, 1416–1425 (2007).
pubmed: 17182155
Wahid, R. et al. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27
pubmed: 21146460
Jin, C. et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet 390, 2472–2480 (2017).
pubmed: 28965718
pmcid: 5720597
Martin, L. B. et al. Status of paratyphoid fever vaccine research and development. Vaccine 34, 2900–2902 (2016).
pubmed: 27083427
Gat, O. et al. Cell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines. PLoS Negl. Trop. Dis. 5, e1373 (2011).
pubmed: 22069504
pmcid: 3206010
Micoli, F. et al. O:2-CRM(197) conjugates against Salmonella Paratyphi A. PLoS ONE 7, e47039 (2012).
pubmed: 23144798
pmcid: 3492368
Tennant, S. M., MacLennan, C. A., Simon, R., Martin, L. B. & Khan, M. I. Nontyphoidal salmonella disease: current status of vaccine research and development. Vaccine 34, 2907–2910 (2016).
pubmed: 27032517
Lanzilao, L. et al. Strain selection for generation of O-antigen-based glycoconjugate vaccines against invasive nontyphoidal salmonella disease. PLoS ONE 10, e0139847 (2015).
pubmed: 26445460
pmcid: 4596569
Watson, D. C., Robbins, J. B. & Szu, S. C. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect. Immun. 60, 4679–4686 (1992).
pubmed: 1383154
pmcid: 258218
Simon, R. et al. Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS ONE 8, e64680 (2013).
pubmed: 23741368
pmcid: 3669428
Micoli, F. et al. Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella. Proc. Natl Acad. Sci. USA 115, 10428–10433 (2018).
pubmed: 30262653
pmcid: 6187145
Mani, S., Wierzba, T. & Walker, R. I. Status of vaccine research and development for Shigella. Vaccine 34, 2887–2894 (2016).
pubmed: 26979135
van der Put, R. M. et al. A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity. Bioconjug. Chem. 27, 883–892 (2016).
pubmed: 26918643
Hatz, C. F. et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: a single blind, partially randomized phase I study. Vaccine 33, 4594–4601 (2015).
pubmed: 26162850
Riddle, M. S. et al. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin. Vaccine Immunol. 23, 908–917 (2016).
pubmed: 27581434
pmcid: 5139601
Obiero, C. W. et al. A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front. Immunol. 8, 1884 (2017).
pubmed: 29375556
pmcid: 5763125
Micoli, F. & MacLennan, C. A. Outer membrane vesicle vaccines. Semin. Immunol. 25, 87–88 (2020).
Martinez-Becerra, F. J. et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect. Immun. 80, 1222–1231 (2012).
pubmed: 22202122
pmcid: 3294653
Pore, D. & Chakrabarti, M. K. Outer membrane protein A (OmpA) from Shigella flexneri 2a: a promising subunit vaccine candidate. Vaccine 31, 3644–3650 (2013).
pubmed: 23764536
Steer, A. C. et al. Status of research and development of vaccines for Streptococcus pyogenes. Vaccine 34, 2953–2958 (2016).
pubmed: 27032515
McNeil, S. A. et al. Safety and immunogenicity of 26-valent group A Streptococcus vaccine in healthy adult volunteers. Clin. Infect. Dis. 41, 1114–1122 (2005).
pubmed: 16163629
Dale, J. B., Penfound, T. A., Chiang, E. Y. & Walton, W. J. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. Vaccine 29, 8175–8178 (2011).
pubmed: 21920403
pmcid: 3195966
Steer, A. C., Law, I., Matatolu, L., Beall, B. W. & Carapetis, J. R. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect. Dis. 9, 611–616 (2009).
pubmed: 19778763
Batzloff, M. R. et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J. Infect. Dis. 187, 1598–1608 (2003).
pubmed: 12721940
Guilherme, L. et al. Towards a vaccine against rheumatic fever. Clin. Dev. Immunol. 13, 125–132 (2006).
pubmed: 17162355
pmcid: 2270766
Sheel, M., Moreland, N. J., Fraser, J. D. & Carapetis, J. Development of group A streptococcal vaccines: an unmet global health need. Expert Rev. Vaccines 15, 227–238 (2016).
pubmed: 26559880
Pandey, M. et al. A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia. J. Immunol. 194, 5915–5925 (2015).
pubmed: 25980008
Bensi, G. et al. Multi high-throughput approach for highly selective identification of vaccine candidates: the group A Streptococcus case. Mol Cell Proteomics 11, M111.015693 (2012).
pubmed: 22286755
pmcid: 3433891
Rivera-Hernandez, T. et al. An experimental group a streptococcus vaccine that reduces pharyngitis and tonsillitis in a nonhuman primate model. mBio https://doi.org/10.1128/mBio.00693-19 (2019).
doi: 10.1128/mBio.00693-19
pubmed: 31040243
pmcid: 6495378
Kabanova, A. et al. Evaluation of a group A Streptococcus synthetic oligosaccharide as vaccine candidate. Vaccine 29, 104–114 (2010).
pubmed: 20870056
Henningham, A. et al. Virulence role of the GlcNAc side chain of the Lancefield cell wall carbohydrate antigen in non-M1-serotype group A Streptococcus. mBio https://doi.org/10.1128/mBio.02294-17 (2018).
doi: 10.1128/mBio.02294-17
pubmed: 29382733
pmcid: 5790915
Schodel, F. et al. Clinical development strategy for a candidate group A streptococcal vaccine. Vaccine 35, 2007–2014 (2017).
pubmed: 28318768
Gamez-Gonzalez, L. B., Hamada, H., Llamas-Guillen, B. A., Ruiz-Fernandez, M. & Yamazaki-Nakashimada, M. BCG and Kawasaki disease in Mexico and Japan. Hum. Vaccin. Immunother. 13, 1091–1093 (2017).
pubmed: 28281896
pmcid: 5443388
Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470–480 (2014).
pubmed: 24336911
Nemes, E. et al. Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N. Engl. J. Med. 379, 138–149 (2018).
pubmed: 29996082
pmcid: 5937161
Tait, D. R. et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 381, 2429–2439 (2019).
pubmed: 31661198
Van Der Meeren, O. et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N. Engl. J. Med. 379, 1621–1634 (2018).
Vekemans, J., O’Brien, K. L. & Farrar, J. Tuberculosis vaccines: rising opportunities. PLoS Med. 16, e1002791 (2019).
pubmed: 31013268
pmcid: 6478266
FAO Global Forum on Food Security and Nutrition, http://www.fao.org/3/cb0863en/cb0863en.pdf
Cabral, M. P. et al. Design of live attenuated bacterial vaccines based on D-glutamate auxotrophy. Nat. Commun. 8, 15480 (2017).
pubmed: 28548079
Micoli, F. et al. Glycoconjugate vaccines: current approaches towards faster vaccine design. Expert Rev. Vaccines 18, 881–895 (2019).
pubmed: 31475596
Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).
pubmed: 32967006
Sevilla, J. P., Bloom, D. E., Cadarette, D., Jit, M. & Lipsitch, M. Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proc. Natl Acad. Sci. USA 115, 12911–12919 (2018).
pubmed: 30559203
pmcid: 6305008
Roope, L. S. J. et al. The challenge of antimicrobial resistance: what economics can contribute. Science 364, eaau4679 (2019). This article highlights prospects for future research on the economics of AMR.
pubmed: 30948524
Bloom, D. E., Black, S., Salisbury, D. & Rappuoli, R. Antimicrobial resistance and the role of vaccines. Proc. Natl Acad. Sci. USA 115, 12868–12871 (2018). This article highlights that an integrated strategy that includes antibiotics, vaccines, diagnostic tools, antibodies and new tools targeting the host or the microbiome or delivered by bacteriophages is required to fight AMR effectively.
pubmed: 30559204
pmcid: 6305009
Balsells, E. et al. Infection prevention and control of Clostridium difficile: a global review of guidelines, strategies, and recommendations. J. Glob. Health 6, 020410 (2016).
pubmed: 28028434
pmcid: 5140074
Peng, Z. et al. Update on antimicrobial resistance in clostridium difficile: resistance mechanisms and antimicrobial susceptibility testing. J. Clin. Microbiol. 55, 1998–2008 (2017).
pubmed: 28404671
pmcid: 5483901
Asadi Karam, M. R., Habibi, M. & Bouzari, S. Urinary tract infection: pathogenicity, antibiotic resistance and development of effective vaccines against uropathogenic Escherichia coli. Mol. Immunol. 108, 56–67 (2019).
pubmed: 30784763
Kourtis, A. P. et al. Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin-susceptible Staphylococcus aureus bloodstream infections - United States. MMWR Morb. Mortal. Wkly. Rep. 68, 214–219 (2019).
pubmed: 30845118
pmcid: 6421967
Unemo, M., Del Rio, C. & Shafer, W. M. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.EI10-0009-2015 (2016).
doi: 10.1128/microbiolspec.EI10-0009-2015
pubmed: 27337478
El Zowalaty, M. E. et al. Pseudomonas aeruginosa: arsenal of resistance mechanisms, decades of changing resistance profiles, and future antimicrobial therapies. Future Microbiol. 10, 1683–1706 (2015).
pubmed: 26439366
Munoz-Price, L. S. et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13, 785–796 (2013).
pubmed: 23969216
pmcid: 4673667
Dyson, Z. A., Klemm, E. J., Palmer, S. & Dougan, G. Antibiotic resistance and typhoid. Clin. Infect. Dis. 68, S165–s170 (2019).
pubmed: 30845331
pmcid: 6405283
Qamar, F. N., Azmatullah, A., Kazi, A. M., Khan, E. & Zaidi, A. K. A three-year review of antimicrobial resistance of Salmonella enterica serovars Typhi and Paratyphi A in Pakistan. J. Infect. Dev. Ctries. 8, 981–986 (2014).
pubmed: 25116662
Kariuki, S., Gordon, M. A., Feasey, N. & Parry, C. M. Antimicrobial resistance and management of invasive Salmonella disease. Vaccine 33, C21–C29 (2015).
pubmed: 25912288
pmcid: 4469558
Gordon, M. A. et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin. Infect. Dis. 46, 963–969 (2008).
pubmed: 18444810
Puzari, M., Sharma, M. & Chetia, P. Emergence of antibiotic resistant Shigella species: a matter of concern. J. Infect. Public Health 11, 451–454 (2018).
pubmed: 29066021
Zafar, A. et al. Antibiotic susceptibility in Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes in Pakistan: a review of results from the Survey of Antibiotic Resistance (SOAR) 2002-15. J. Antimicrob. Chemother. 71, i103–i109 (2016).
pubmed: 27048578
pmcid: 4890355
US Department of Health and Human Services. Antibiotic resistance threats in the United States. https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf (2013).
Gandhi, N. R. et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375, 1830–1843 (2010).
pubmed: 20488523
Nguyen, L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch. Toxicol. 90, 1585–1604 (2016).
pubmed: 27161440
pmcid: 4988520
Marston, H. D., Paules, C. I. & Fauci, A. S. Monoclonal antibodies for emerging infectious diseases - borrowing from history. N. Engl. J. Med. 378, 1469–1472 (2018).
pubmed: 29513615
McConnell, M. J. Where are we with monoclonal antibodies for multidrug-resistant infections? Drug Discov. Today 24, 1132–1138 (2019).
pubmed: 30853568
DiGiandomenico, A. et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci. Transl. Med. 6, 262ra155 (2014).
pubmed: 25391481
Lowy, I. et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197–205 (2010).
pubmed: 20089970
Gulati, S. et al. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 17, e3000323 (2019).
pubmed: 31216278
pmcid: 6602280
Fischetti, V. A. Development of phage lysins as novel therapeutics: a historical perspective. Viruses 10, 310 (2018).
pmcid: 6024357
Merabishvili, M. et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE 4, e4944 (2009).
pubmed: 19300511
pmcid: 2654153
Sahota, J. S. et al. Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J. Aerosol Med. Pulm. Drug Deliv. 28, 353–360 (2015).
pubmed: 25714328
Nale, J. Y. et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob. Agents Chemother. 60, 968–981 (2016).
pubmed: 26643348
pmcid: 4750681
Lima, R., Del Fiol, F. S. & Balcao, V. M. Prospects for the use of new technologies to combat multidrug-resistant bacteria. Front. Pharmacol. 10, 692 (2019).
pubmed: 31293420
pmcid: 6598392
Relman, D. A. & Lipsitch, M. Microbiome as a tool and a target in the effort to address antimicrobial resistance. Proc. Natl Acad. Sci. USA 115, 12902–12910 (2018).
pubmed: 30559176
pmcid: 6304941
Khanna, S. et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J. Infect. Dis. 214, 173–181 (2016).
pubmed: 26908752
Gerding, D. N. et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. JAMA 313, 1719–1727 (2015).
pubmed: 25942722
Kim, W. J. et al. Commensal Neisseria kill Neisseria gonorrhoeae through a DNA-dependent mechanism. Cell Host Microbe 26, 228–239.e8 (2019).
pubmed: 31378677
pmcid: 6728082
Idelevich, E. A. & Becker, K. How to accelerate antimicrobial susceptibility testing. Clin. Microbiol. Infect. 25, 1347–1355 (2019).
pubmed: 31055166
van Belkum, A. et al. Developmental roadmap for antimicrobial susceptibility testing systems. Nat. Rev. Microbiol. 17, 51–62 (2019).
pubmed: 30333569
Li, W. et al. Rapid identification and antimicrobial susceptibility testing for urinary tract pathogens by direct analysis of urine samples using a MALDI-TOF MS-based combined protocol. Front. Microbiol. 10, 1182 (2019).
pubmed: 31231323
pmcid: 6560049
Rappuoli, R. Glycoconjugate vaccines: principles and mechanisms. Sci. Transl. Med. 10, eaat4615 (2018).
pubmed: 30158151
Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Mol. Med. 6, 708–720 (2014).
pubmed: 24803000
pmcid: 4203350
Serruto, D., Serino, L., Masignani, V. & Pizza, M. Genome-based approaches to develop vaccines against bacterial pathogens. Vaccine 27, 3245–3250 (2009).
pubmed: 19200820
Serruto, D., Bottomley, M. J., Ram, S., Giuliani, M. M. & Rappuoli, R. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 30, B87–B97 (2012).
pubmed: 22607904
Moriel, D. G. et al. Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc. Natl Acad. Sci. USA 107, 9072–9077 (2010).
pubmed: 20439758
pmcid: 2889118
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469–481 (2016).
pubmed: 27022144
pmcid: 4821650
Crank, M. C. et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365, 505–509 (2019).
pubmed: 31371616
Scarselli, M. et al. Rational design of a meningococcal antigen inducing broad protective immunity. Sci. Transl. Med. 3, 91ra62 (2011).
pubmed: 21753121
Gnopo, Y. M. D., Watkins, H. C., Stevenson, T. C., DeLisa, M. P. & Putnam, D. Designer outer membrane vesicles as immunomodulatory systems-reprogramming bacteria for vaccine delivery. Adv. Drug Deliv. Rev. 114, 132–142 (2017).
pubmed: 28501509
Gerke, C. et al. Production of a shigella sonnei vaccine based on generalized modules for membrane antigens (GMMA), 1790GAHB. PLoS ONE 10, e0134478 (2015).
pubmed: 26248044
pmcid: 4527750
Launay, O. et al. Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine 22, 164–172 (2017).
pubmed: 28735965
pmcid: 5552227
Launay, O. et al. Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results from a phase 1 clinical trial. Front. Immunol. 10, 335 (2019).
pubmed: 30906291
pmcid: 6418009
Wacker, M. et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298, 1790–1793 (2002).
pubmed: 12459590
Kampf, M. M. et al. In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation. Microb. Cell Fact. 14, 12 (2015).
pubmed: 25612741
pmcid: 4308876
Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597–1608 (2013).
pubmed: 24309663
Otieno, L. et al. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Lancet Infect. Dis. 16, 1134–1144 (2016).
pubmed: 27394191
Cunningham, A. L. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N. Engl. J. Med. 375, 1019–1032 (2016).
pubmed: 27626517